References in Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial - The Lancet Oncology
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study | Journal for ImmunoTherapy of Cancer
Combinatorial benefit without synergy in recent clinical trials of immune checkpoint inhibitors | medRxiv
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | NEJM
![PDF] Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/23dbeed54cde655fb6a12697b02c9ff303515da7/11-Table2-1.png "PDF] Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | Semantic Scholar")
PDF] Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | Semantic Scholar
Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study - European Journal of Cancer
PDF) Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer | Nature
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Evolving impact of long-term survival results on metastatic melanoma treatment | Journal for ImmunoTherapy of Cancer
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆ - ESMO Open
NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
PDF) Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter
Nivolumab Combined with Ipilimumab
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology
Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial -
Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study - European Journal of Cancer
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma
![PDF] Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e9421b1f28d07120db03e4bd48eb87e8e203563c/14-Figure2-1.png "PDF] Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma | Semantic Scholar")
PDF] Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma | Semantic Scholar
